Germany· DE-A57-03dd59eb45f5c4f0

Lampit

A nifurtimox product containing nifurtimox, registered in Germany by Bayer Vital Gmbh. The same ATC class is registered in 4 of our 19 countries.

ATC P01CC01

Checked against EMA Article 57 (European Union) on

Informational only — not a medical device.

SOURCE REGISTER · DEEMA Article 57 (European Union)normalisedLampitATCP01CC01REGISTER NO.DE-A57-03dd59eb45f5c4…PACKS LISTED0CHECKEDSeptember 30, 2026

Where it is registered

Nifurtimox is registered in 4 of 19 countries.

Countries holding a registration under ATC P01CC01 (nifurtimox), each read from that country’s own register.

  • This record: Germany, from EMA Article 57 (European Union)
  • 2 of them publish a price we can compare per daily dose

Nifurtimox · ATC P01CC01

4 / 19 countries

  • Germany
  • Spainprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

EMA Article 57 (European Union)
Active substance
Nifurtimox
Manufacturer
Bayer Vital Gmbh
Country
Germany (DE)
ATC code
P01CC01
ATC class
Nifurtimox
Defined daily dose
0.7 g, O
Reimbursed
Not published by this register
Source register
EMA Article 57 (European Union)
Last checked
September 30, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

7 interactions on record for nifurtimox.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Nifurtimox · interactions on record

7 records

  • 4 severe
  • 3 moderate

Most severe, free to view

  • EthanolB05XX04severe
  • EthanolV03AB16severe
  • EthanolV03AZ01severe
  • EthanolV07AB03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nifurtimox in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nifurtimox products

Authorised across Europe · EMA

The same active substance is authorised in 1 EEA country. Names it is sold under:

  • Spain · Lampit

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7d4fccbc-adbb-46f4-935b-163a0daba6c8
GET /v1/drugs/7d4fccbc-adbb-46f4-935b-163a0daba6c8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pzn": null,
  "route": "Oral Use",
  "source": "ema_art57_de",
  "ma_number": null,
  "substance": "Nifurtimox",
  "atc_from_source": null,
  "authorisation_country": "Germany"
}

See everything about nifurtimox.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.